Spravato® (esketamine) rejected by NICE for treatment-resistant depression
4 September 2020 Spravato® (esketamine) receives second rejection by NICE for treatment-resistant depression On 3 September 2020, the National Institute for Health and Care Excellence (NICE) published a second draft guidance for Spravato® (esketamine) nasal spray in combination with a selective serotonin reuptake inhibitor or serotonin and norepinephrine reuptake inhibitor, for adults living with treatment-resistant major depressive disorder who have not responded to at least two different antidepressants. The nasal spray has been rejected for a second time due to uncertainties surrounding its cost. Esketamine was first rejected by NICE in January following concerns over its clinical and cost–effectiveness. However,...